BioMark Diagnostics Completes Testing of over 5,400 Subjects as Part of a Validation Study for Early Lung Cancer Detection
BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) has successfully completed a major clinical trial for its early lung cancer detection assay. The study, conducted in collaboration with IUCPQ, analyzed over 5,400 patient samples, including 2,500 archived samples and 2,900 high-risk participants. This marks the largest clinical study validating a metabolite-based assay for lung cancer screening.
CEO Rashid Bux highlighted the trial's significance, emphasizing its diverse patient pool and real-world representation. BioMark has partnered with a leading data analytics group to analyze the vast amount of data collected. The company plans to present the results at an upcoming medical conference and submit them for publication in a peer-reviewed journal, aiming to make the innovative technology available to patients as soon as possible.
BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ha completato con successo un importante studio clinico per il suo test di rilevamento precoce del cancro ai polmoni. Lo studio, condotto in collaborazione con IUCPQ, ha analizzato oltre 5.400 campioni di pazienti, inclusi 2.500 campioni archiviati e 2.900 partecipanti ad alto rischio. Questo segna il più grande studio clinico per convalidare un test basato su metaboliti per lo screening del cancro ai polmoni.
Il CEO Rashid Bux ha sottolineato l'importanza dello studio, evidenziando la diversità del campione di pazienti e la sua rappresentatività nel mondo reale. BioMark ha collaborato con un importante gruppo di analisi dei dati per esaminare la vasta quantità di dati raccolti. L'azienda prevede di presentare i risultati a una prossima conferenza medica e di inviarli per la pubblicazione in una rivista peer-reviewed, con l'obiettivo di rendere disponibile la tecnologia innovativa ai pazienti il prima possibile.
BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ha completado con éxito un importante ensayo clínico para su prueba de detección temprana de cáncer de pulmón. El estudio, realizado en colaboración con IUCPQ, analizó más de 5,400 muestras de pacientes, incluyendo 2,500 muestras archivadas y 2,900 participantes de alto riesgo. Esto marca el mayor estudio clínico que valida un ensayo basado en metabolitos para el cribado de cáncer de pulmón.
El CEO Rashid Bux destacó la importancia del ensayo, enfatizando la diversidad del grupo de pacientes y su representación en el mundo real. BioMark se ha asociado con un grupo líder en análisis de datos para analizar la vasta cantidad de datos recopilados. La compañía planea presentar los resultados en una próxima conferencia médica y enviarlos para su publicación en una revista revisada por pares, con el objetivo de hacer que la tecnología innovadora esté disponible para los pacientes lo antes posible.
BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF)는 조기 폐암 검출 검사법에 대한 주요 임상 시험을 성공적으로 완료했습니다. IUCPQ와 협력하여 진행된 이 연구는 2,500개의 보관 샘플과 2,900명의 고위험 참가자를 포함하여 5,400개 이상의 환자 샘플을 분석했습니다. 이는 폐암 선별을 위한 대사물질 기반 검사법을 검증하는 가장 큰 임상 연구를 의미합니다.
CEO 라시드 벅스는 연구의 중요성을 강조하며 다양한 환자 풀과 실제 세계에서의 대표성을 강조했습니다. BioMark는 방대한 데이터를 분석하기 위해 선도적인 데이터 분석 그룹과 파트너십을 맺었습니다. 이 회사는 향후 의료 회의에서 결과를 발표하고 동료 검토 저널에 발표하기 위해 제출할 계획이며, 가능한 한 빨리 환자에게 혁신적인 기술을 제공하는 것을 목표로 하고 있습니다.
BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) a réussi à achever un essai clinique majeur pour son test de détection précoce du cancer du poumon. L'étude, réalisée en collaboration avec IUCPQ, a analysé plus de 5 400 échantillons de patients, y compris 2 500 échantillons archivés et 2 900 participants à haut risque. Cela marque la plus grande étude clinique validant un test basé sur les métabolites pour le dépistage du cancer du poumon.
Le PDG Rashid Bux a souligné l'importance de l'essai, en mettant l'accent sur la diversité du groupe de patients et sa représentation dans le monde réel. BioMark s'est associée à un groupe d'analyse de données de premier plan pour analyser la grande quantité de données recueillies. L'entreprise prévoit de présenter les résultats lors d'une prochaine conférence médicale et de les soumettre à une revue par des pairs, avec l'objectif de rendre la technologie innovante disponible pour les patients le plus rapidement possible.
BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) hat erfolgreich eine bedeutende klinische Studie für seinen Test zur frühen Lungenkrebserkennung abgeschlossen. Die Studie, die in Zusammenarbeit mit IUCPQ durchgeführt wurde, analysierte über 5.400 Patientenproben, darunter 2.500 archivierte Proben und 2.900 Hochrisikopatienten. Dies markiert die größte klinische Studie, die einem metabolitbasierten Test zur Lungenkrebsvorsorge Validität verleiht.
CEO Rashid Bux hob die Bedeutung der Studie hervor und betonte die Vielfalt der Patientengruppe und deren reale Repräsentation. BioMark hat sich mit einer führenden Datenanalytikgruppe zusammengetan, um die umfangreichen gesammelten Daten zu analysieren. Das Unternehmen plant, die Ergebnisse auf einer kommenden medizinischen Konferenz vorzulegen und zur Veröffentlichung in einer von Experten begutachteten Zeitschrift einzureichen, mit der Absicht, die innovative Technologie so schnell wie möglich den Patienten zur Verfügung zu stellen.
- Successful completion of a large-scale clinical trial with over 5,400 patient samples
- Collaboration with a reputable institution (IUCPQ) for the study
- Diverse patient pool including high-risk individuals eligible for lung cancer screening
- Partnership with a leading data analytics group for robust AI and machine learning analysis
- Plans to present results at a medical conference and submit for peer-reviewed publication
- None.
Largest Clinical Study Validating a Metabolite-based Assay for Lung Cancer Screening
Vancouver, British Columbia--(Newsfile Corp. - September 10, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF), a leading developer of liquid biopsy tests for early cancer detection, is pleased to announce today the successful completion of a significant clinical trial in collaboration with the Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ). Over 5,400 patient samples were analyzed using BioMark's innovative lung cancer assay, demonstrating the test's potential to revolutionize early detection and improve patient outcomes.
"This is a pivotal moment for BioMark's early lung cancer assay," said Rashid Bux, CEO and President of BioMark. "The trial launched in February 2022 was designed to encompass a diverse patient pool, including prospectively collected archived samples from about 2,500 patients and enrollment of over 2,900 participants classified as at high risk for lung cancer and eligible for screening in an established and well-defined lung cancer screening cohort. The successful testing of samples representative of the real world is a major milestone for BioMark and underscores the immense potential of our liquid biopsy technology to revolutionize early detection and improve patient outcomes in lung cancer."
BioMark has partnered with a leading data analytics group possessing robust artificial intelligence and machine learning capabilities to analyze the vast amount of data collected during the trial. The results of the study will be presented at an upcoming medical conference and submitted for publication in a peer-reviewed journal. BioMark is committed to advancing the development of its lung cancer assay and making it available to patients in need as soon as possible. This innovative technology has the potential to significantly improve early detection rates and treatment outcomes for this devastating disease.
About BioMark Diagnostics Inc.
BioMark Diagnostics Inc. is a leading developer of liquid biopsy tests for the early detection of cancer that leverages the power of metabolomics and machine learning algorithms. The company's proprietary technology utilizes a simple blood draw to detect the presence of cancer-associated biomarkers, enabling earlier diagnosis and improved patient outcomes. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. BioMark is committed to developing innovative and accessible diagnostic solutions to address unmet medical needs in oncology.
Further information about BioMark is available under its profile on the SEDAR+ website www.sedarplus.ca and the CSE website https://thecse.com/.
For further information on BioMark, please Contact:
Rashid Ahmed Bux
President & CEO
BioMark Diagnostics Inc.
Tel. 604-370-0779
Email: info@biomarkdiagnostics.com
Forward-Looking Information:
This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events, or results or otherwise, other than as required by applicable securities laws.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/222771
FAQ
How many patient samples were analyzed in BioMark Diagnostics' lung cancer detection study?
What is the significance of BioMark's (BMKDF) recent clinical trial for lung cancer detection?
When did BioMark Diagnostics (BMKDF) launch the lung cancer detection trial?
What are BioMark's (BMKDF) plans for the results of their lung cancer detection study?
